Gamma-Delta T Cell Therapy Pipeline — PatSnap Eureka
Gamma-Delta T Cell Therapy Pipeline: Solid Tumors & Hematologic Malignancies
γδ T cells offer MHC-independent tumor cytotoxicity that bridges innate and adaptive immunity — making them uniquely suited for allogeneic "off-the-shelf" cancer cell therapies across AML, GBM, HCC, myeloma, and beyond. Explore the full pipeline of CAR engineering, bispecific engagers, and adoptive transfer platforms.
γδ T Cell Subset Distribution
Vγ9Vδ2 dominates peripheral blood; Vδ1 enriched in tumor-infiltrating lymphocytes
From AML to Glioblastoma: The γδ T Cell Oncology Map
Retrieved results address γδ T cell applications across a broad oncological landscape, encompassing hematologic malignancies — including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), B-cell malignancies, and multiple myeloma — as well as solid tumors including hepatocellular carcinoma (HCC), glioblastoma (GBM), melanoma, colon cancer, renal cell carcinoma (RCC), osteosarcoma, and lung and liver cancers.
At the molecular level, two principal γδ TCR subsets serve as therapeutic anchors. The Vγ9Vδ2 subset constitutes ~50–90% of circulating γδ T cells and is activated by phosphoantigens derived from dysregulated mevalonate pathway activity in tumor cells. Aminobisphosphonates such as zoledronate potentiate phosphoantigen accumulation by inhibiting farnesyl pyrophosphate synthase, making tumor cells preferentially susceptible. The Vδ1 subset is enriched in mucosal tissues and tumor-infiltrating lymphocyte (TIL) populations, recognizing MHC class I-related stress molecules (MICA, MICB, ULBPs). Retrieved results suggest Vδ1 cells may be superior to Vδ2 for certain solid tumors due to tissue tropism and greater intratumoral persistence.
Key checkpoint and exhaustion markers — PD-1, TIM-3, TIGIT, and CD39 — are co-expressed on tumor-infiltrating and bone marrow-resident γδ T cells in AML and myeloma patients, representing both a liability and a therapeutic target for combination strategies. Learn how PatSnap's life sciences intelligence maps these evolving target landscapes.
Six Approaches Driving the γδ T Cell Pipeline
From first-generation phosphoantigen activation to CAR engineering and bispecific engagers — the γδ T cell field has intensified activity across multiple modalities simultaneously.
In Vivo Phosphoantigen & Aminobisphosphonate Activation
The earliest and most clinically explored approach involves systemic administration of nitrogen-containing bisphosphonates (N-BPs, e.g., zoledronate) alone or combined with low-dose IL-2 to induce in vivo expansion of peripheral Vγ9Vδ2 T cells. Early-phase clinical trials across solid tumors and hematologic malignancies have confirmed a low toxicity profile. Key limitations include activation-induced anergy after repeated dosing and modest efficacy in advanced patients with low baseline γδ T cell counts.
Clinically explored · Low toxicity confirmedEx Vivo Expansion & Adoptive Transfer
Expansion of γδ T cells from PBMCs using zoledronate, IL-2, IL-15, IL-21, or CD3/CD28 activators, followed by adoptive infusion. Protocols generating >185-fold γδ T cell expansion (>98% CD3+, >99% γδTCR+ purity) suitable for clinical-scale manufacture have been described. Allogeneic Vγ9Vδ2 T cells from healthy donors transferred to late-stage lung and liver cancer patients demonstrated promising clinical safety and prolonged survival. IL-21 supplementation rescues "non-expander" donors.
>185-fold expansion · >98% CD3+ purityCAR-Engineered γδ T Cells
Engineering of γδ T cells with chimeric antigen receptors (CARs) combines native MHC-independent cytotoxicity with CAR-directed tumor antigen specificity. Vδ1 and Vδ2 subsets can both be successfully transduced. Critically, γδ CAR-T cells retain antigen-presenting cell function — a property not shared by conventional αβ CAR-T cells. PatSnap analytics tracks Adicet Bio's active patents covering anti-GPC3, anti-CD20, and anti-BCMA CAR constructs with sIL-15 co-expression for persistence enhancement.
Retains APC function · Adicet Bio IP-activeBispecific Engager Molecules
Bispecific antibodies or fusion proteins simultaneously bind γδ TCR components and tumor surface antigens, selectively recruiting γδ T cells to tumor targets. An anti-TRGV9/anti-CD123 bispecific antibody selectively activates Vγ9+ γδ T cells and redirects them to CD123+ AML blasts, avoiding pan-CD3+ T cell-related toxicity. GAB molecules from Utrecht Medical Center link γδ9δ2 TCR extracellular domains to a CD3-binding moiety, enabling αβ T cell-mediated phosphoantigen-dependent tumor recognition. Shattuck Labs' GADLEN constructs use butyrophilin domains fused to anti-CD19/anti-CD20 fragments.
No ex vivo modification needed · AML-targetedGene Therapy & Viral Vector-Based Activation
American Gene Technologies International filed multiple active patents in the IL jurisdiction covering gene therapy approaches to activate γδ T cells, with priority tracing to a 2016 provisional application. These filings describe compositions and methods for increased γδ T cell activation in the context of cancers and infectious diseases, representing an IP platform combining viral vector delivery with γδ T cell immunotherapy. Four active IL-jurisdiction patents all trace to a single 2016 provisional application, indicating a sustained prosecution strategy.
4 active patents · 2016 priority dateOpsonin-Secreting & Cytokine-Primed Platforms
A UCL Cancer Institute group described an "OPS-γδ" platform engineering Vγ9Vδ2 T cells to secrete synthetic opsonins and stabilized IL-15 (stIL-15), enabling both direct cytotoxicity and bystander immunity recruitment for solid tumors using GD2 as a model antigen. This avoids tonic CAR signaling while leveraging innate ADCC mechanisms. Separately, IL-12/18/21 pre-activation of γδ T cells significantly enhanced anti-tumor efficacy in melanoma and HCC murine models and overcame resistance to anti-PD-L1 treatment.
OPS-γδ · Overcomes PD-L1 resistanceKey Metrics Across the γδ T Cell Therapy Pipeline
Data points derived from patent filings and peer-reviewed literature in this dataset, as analysed via PatSnap Eureka.
Therapeutic Modalities by Clinical Maturity
In vivo N-BP activation is the most clinically explored; CAR engineering and bispecific engagers are emerging with active IP filings.
Key Molecular Targets by Indication Type
Molecular targets distributed across hematologic malignancies and solid tumors, with checkpoint markers relevant to both.
Ex Vivo Expansion Quality Benchmarks
Clinical-scale manufacturing protocols achieve >185-fold expansion with >98% CD3+ and >99% γδTCR+ purity, enabling allogeneic "off-the-shelf" production.
Commercial Assignee IP Activity Distribution
Adicet Bio leads patent activity in this dataset; American Gene Technologies holds 4 active IL-jurisdiction patents from a single 2016 priority application.
Commercial Patent Filers & Academic Leaders in γδ T Cell Therapy
Patent-driven activity is concentrated in dedicated cell therapy companies; academic institutions drive mechanistic and clinical translation signals.
| Assignee | Type | Key Claims / Focus | Jurisdictions | Status |
|---|---|---|---|---|
| Adicet Bio / Adicet Therapeutics | Commercial | CAR-γδ T cells: anti-GPC3 (HCC), anti-CD20/BCMA (hematologic); sIL-15 co-expression | IL, SG, EP | Active |
| American Gene Technologies International | Commercial | Gene therapy + γδ T cell activation; viral vector delivery; 4 patents from 2016 provisional | IL | Active |
| TC Biopharm Ltd | Commercial | Allogeneic & autologous γδ T cell preparation; combination with PD-1/PD-L1/CTLA-4 inhibitors | IL | Active |
| Immatics US | Commercial | αβ-TCR depletion during γδ T cell expansion; transgene expression in purified γδ populations | EP | Active (2025) |
| Shattuck Labs | Commercial | GADLEN heterodimeric proteins; BTN3A1/3A2 + BTNL3/8 fused to anti-CD19/CD20 fragments | IL, SG | Pending |
| UCL Cancer Institute / UCL Child Health | Academic | Vδ1 TIL characterisation; CAR-γδ T cells; OPS-γδ opsonin-secreting platform; GD2 targeting | Literature | Active |
| Jinan University / Beijing DCTY Biotech | Academic / Commercial | Clinical allogeneic Vγ9Vδ2 transfer; lung and liver cancer; γδ T cell industry positioning | Literature | Clinical Data |
Track γδ T Cell IP Filings in Real Time
PatSnap Eureka monitors new patent publications across all jurisdictions — set alerts for Adicet Bio, TC Biopharm, and emerging assignees.
What the Pipeline Signals for γδ T Cell Development
Key strategic read-outs from patent and literature analysis via PatSnap Eureka for R&D teams and IP professionals.
Allogeneic "Off-the-Shelf" Is the Priority Modality
Multiple commercial entities — Adicet Bio, TC Biopharm, Immatics US — have filed active patents covering allogeneic γδ T cell manufacturing and engineering. The MHC-independence of γδ T cells is a foundational advantage for universal donor product development, and retrieved results suggest the field is prioritising this modality over autologous approaches. See how leading cell therapy teams use PatSnap for competitive intelligence.
CAR-γδ Is Differentiating from Conventional αβ CAR-T
Unlike αβ CAR-T, γδ CAR-T cells retain antigen-presenting cell function and innate NKG2D-mediated cytotoxicity. Retrieved patent data from Adicet Bio shows claims specifically for CD20/BCMA CAR-γδ (hematologic) and GPC3 CAR-γδ (solid tumor), suggesting disease-area-specific product differentiation strategies. Explore the PatSnap analytics platform for CAR construct landscape mapping.
Checkpoint Co-Expression Is Both Liability and Target
TIGIT, PD-1, and TIM-3 co-expression on bone marrow-resident Vδ1 T cells in AML and myeloma patients may limit infused product persistence. Retrieved results suggest that rational combination with checkpoint inhibitors — particularly anti-TIGIT — warrants development. TC Biopharm patent claims already reflect this strategic intent, explicitly covering PD-1, PD-L1, and CTLA-4 inhibitor combinations.
Metabolic Reprogramming Offers a Selective Enhancement Strategy
Harvard Medical School data (2021) document that IFN-γ+ antitumoral γδ T cells depend on glycolysis, while pro-tumoral IL-17+ γδ T cells engage oxidative metabolism and lipid uptake (exacerbated in obesity). Glucose supplementation or lipid pathway targeting could selectively enhance antitumoral and suppress pro-tumoral γδ T cell subsets within the tumor microenvironment — a mechanistic angle not yet reflected in commercial patent filings.
Converging Strategies to Overcome γδ T Cell Limitations
TC Biopharm patents explicitly claim combination of γδ T cell products with PD-1, PD-L1, and CTLA-4 inhibitors. Retrieved results demonstrate that IL-12/18/21 cytokine pre-activation of γδ T cells overcomes PD-L1-mediated resistance in murine melanoma and HCC models. Checkpoint co-inhibitory receptor co-expression on bone marrow-resident Vδ1 T cells in AML and myeloma patients suggests that checkpoint blockade combinations may be required to rescue exhausted γδ TILs.
Mechanistic evidence shows that certain chemotherapies — anthracyclines, oxaliplatin, temozolomide — upregulate NKG2D stress ligands on tumor cells and potentiate γδ T cell cytotoxicity. Engineered drug-resistant γδ T cells (via transgenic expression of drug resistance genes) have been described as a strategy to combine TMZ chemotherapy with γδ immunotherapy in glioblastoma. According to NCI research frameworks, chemo-immunotherapy combinations represent a high-priority translational direction.
Advanced γδ T cell genome editing is expected to widen immuno-oncology applications. The PatSnap life sciences platform tracks CRISPR and gene editing patent filings relevant to cell therapy manufacturing. The European Patent Office has seen increasing filings in this area since 2020.
Direct Clinical Evidence from the γδ T Cell Pipeline
The clinical evidence base in this dataset is predominantly early-phase or correlative. No retrieved results explicitly reference Phase II/III trial outcomes for γδ T cell therapies.
Allogeneic Vγ9Vδ2 Transfer in Lung & Liver Cancer
A study from Jinan University (2020) described clinical safety and prolonged survival in late-stage patients receiving allogeneic Vγ9Vδ2 T cells from healthy donors. Humanized mouse models were used for in vivo validation prior to patient transfer. This represents one of the most direct clinical translational signals in this dataset.
Jinan University · 2020 · Phase I safety confirmedN-BP + IL-2 Early-Phase Trials Across Multiple Cancers
Multiple retrieved review papers confirm that early-phase clinical trials using aminobisphosphonates (particularly zoledronate) plus low-dose IL-2 have been conducted across solid tumors and hematologic malignancies with confirmed safety profiles. Nagasaki University describes the clinical trial landscape as of 2015, noting confirmed safety but unsatisfactory efficacy — driving the push toward ex vivo and CAR-based approaches.
Phase I · Confirmed safety · Modest efficacyVδ1 TIL Infusion in Melanoma — Safe & Well Tolerated
UCL Cancer Institute (2012) data document clinical infusion of Vδ1 T cells as part of TIL products in melanoma patients, described as safe and well tolerated. Vδ1 TIL expansion from melanoma TILs reaching >10⁹ cells was confirmed, establishing the feasibility of clinical-scale Vδ1 manufacturing — a key prerequisite for allogeneic solid tumor products.
UCL · Melanoma TIL · >10⁹ cells achievedγδ T Cell Counts Correlate with Deep Molecular Response in CML
A Taiwan-based study (Mackay Memorial Hospital, 2021) documented that γδ T cell counts and Vδ2 subset expansion correlated with achievement of deep molecular response (DMR) in CML patients treated with BCR-ABL tyrosine kinase inhibitors, providing an indirect clinical signal for γδ T cell involvement in treatment outcomes — and a potential biomarker for TKI response monitoring.
CML · TKI therapy · DMR correlationCAR-γδ T Cells for Leukemia — IND-Enabling Preclinical Stage
A 14-day manufacturing process yielding >98% pure γδ T cells was described by Sheba Medical Center, with CAR transduction efficacy demonstrated and CAR-directed and independent anti-leukemia activity reported. This suggests IND-enabling preclinical stage for γδ CAR-T cell approaches in leukemia.
Sheba Medical Center · 14-day mfg · IND-stagePD-1+Foxp3+ γδ T Cell Frequency Correlates with Poor AML Prognosis
Clinical correlation of PD-1+Foxp3+ γδ T cell frequency with poor AML prognosis was demonstrated using TCGA RNA-seq from 167 AML patients, validating checkpoint expression as a clinically relevant phenomenon. This data supports the rationale for combining γδ T cell therapies with checkpoint inhibitors in AML settings. Access PatSnap's secure data environment for sensitive oncology intelligence workflows.
167 AML patients · TCGA RNA-seq · Prognostic biomarkerGamma-Delta T Cell Therapy — Key Questions Answered
Gamma-delta (γδ) T cells represent a functionally distinct lymphocyte population with MHC-independent tumor cytotoxicity, bridging innate and adaptive immunity in a manner that makes them uniquely attractive for both autologous and allogeneic off-the-shelf cancer cell therapies. Unlike conventional αβ CAR-T cells, γδ CAR-T cells retain antigen-presenting cell function and innate NKG2D-mediated cytotoxicity.
The two principal γδ TCR subsets are: (1) Vγ9Vδ2, the dominant peripheral blood subset (~50–90% of circulating γδ T cells), activated by phosphoantigens derived from dysregulated mevalonate pathway activity in tumor cells; and (2) Vδ1, more abundant in mucosal tissues and enriched in tumor-infiltrating lymphocyte (TIL) populations, recognizing MHC class I-related stress molecules (MICA, MICB, ULBPs). Vδ1 cells may be superior to Vδ2 for certain solid tumors due to tissue tropism and greater intratumoral persistence.
In this dataset, Adicet Bio is the most prolific patent assignee, with filings covering engineered γδ T cells for both solid tumors (anti-GPC3, anti-GD2-like) and hematologic malignancies (anti-CD20, anti-BCMA CAR constructs) with sIL-15 co-expression. Other active patent filers include American Gene Technologies International (gene therapy + γδ T cell activation), TC Biopharm Ltd (allogeneic and autologous γδ T cell preparation including checkpoint inhibitor combinations), Immatics US (γδ T cell expansion with αβ-TCR depletion), and Shattuck Labs (GADLEN heterodimeric protein platforms).
Bispecific engager molecules are bispecific antibodies or fusion proteins that simultaneously bind γδ TCR components and tumor surface antigens, selectively recruiting γδ T cells to tumor targets. Examples include an anti-TRGV9/anti-CD123 bispecific antibody for AML that selectively activates Vγ9+ γδ T cells and redirects them to CD123+ AML blasts; gamma delta TCR anti-CD3 bispecific molecules (GABs) developed at Utrecht Medical Center; and GADLEN constructs from Shattuck Labs using butyrophilin domains fused to tumor-targeting antibody fragments.
Multiple converging combination strategies are being explored: (1) γδ T cells combined with checkpoint inhibitors (PD-1/PD-L1, TIGIT, TIM-3) — TC Biopharm patents explicitly claim this combination; (2) γδ T cells combined with conventional chemotherapy, where anthracyclines, oxaliplatin, and temozolomide upregulate NKG2D stress ligands on tumor cells and potentiate γδ T cell cytotoxicity; (3) genome editing to enhance γδ T cell function; (4) metabolic reprogramming targeting glycolysis to selectively enhance antitumoral γδ T cell subsets.
Clinical signals include: allogeneic Vγ9Vδ2 T cell infusion in late-stage lung and liver cancer patients demonstrating clinical safety and prolonged survival (Jinan University, 2020); early-phase clinical trials using aminobisphosphonates plus low-dose IL-2 confirming safety profiles across solid tumors and hematologic malignancies; Vδ1 TIL infusion in melanoma clinical trial described as safe and well tolerated; and γδ T cell counts correlating with deep molecular response in CML patients on TKI therapy. No retrieved results explicitly reference Phase II/III trial outcomes.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About γδ T Cell TherapyAccelerate Your γδ T Cell Research with AI-Powered Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map cell therapy pipelines, track assignee IP activity, and identify emerging molecular targets across oncology.
References
- γδ T Cells: The Ideal Tool for Cancer Immunotherapy — Stanford University (2020)
- Current Advances in γδ T Cell-Based Tumor Immunotherapy — University of Palermo (2017)
- γδ T Cell Immunotherapy — A Review — Nagasaki University (2015)
- Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer — Paracelsus Medical University (2018)
- Vγ9Vδ2 T Cells: Can We Re-Purpose a Potent Anti-Infection Mechanism for Cancer Therapy? — Boehringer Ingelheim RCV (2020)
- Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer — Jinan University (2020)
- Characterization of Donor Variability for γδ T Cell ex vivo Expansion and Development of an Allogeneic γδ T Cell Immunotherapy — Emory University (2020)
- Analysis of Vδ1 T cells in clinical grade melanoma-infiltrating lymphocytes — University of Catania (2012)
- Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation — UCL Institute of Child Health (2018)
- Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia — Sheba Medical Center (2020)
- Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia — Syngene International (2021)
- Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds — Utrecht Medical Center (2021)
- OPS-γδ: allogeneic opsonin-secreting γδT cell immunotherapy for solid tumours mediates direct and bystander immunity — UCL Cancer Institute (2022)
- IL-12/18/21 pre-activation enhances the anti-tumor efficacy of expanded γδT cells and overcomes resistance to anti-PD-L1 treatment — A*STAR Singapore (2022)
- Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion — Antwerp University Hospital (2018)
- Activated naïve γδ T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia — Mackay Memorial Hospital, Taiwan (2021)
- Distinct metabolic programs established in the thymus control effector functions of γδ T cell subsets in tumor microenvironments — Harvard Medical School (2021)
- Single-cell RNA sequencing of human breast tumour-infiltrating immune cells reveals a γδ T-cell subtype associated with good clinical outcome — University of Edinburgh (2020)
- Engineered Drug Resistant γδ T Cells Kill Glioblastoma Cell Lines during a Chemotherapy Challenge — Emory University (2013)
- A close look at current γδ T-cell immunotherapy — Beijing DCTY Biotech (2023)
- National Institutes of Health (NIH) — Referenced for zoledronate mechanism context
- National Cancer Institute (NCI) — Referenced for chemo-immunotherapy combination frameworks
- European Patent Office (EPO) — Referenced for genome editing and cell therapy patent filing context
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This page represents a snapshot of innovation signals within a targeted dataset and should not be interpreted as a comprehensive view of the full clinical pipeline or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.